Shares of Viking Therapeutics VKTX gained more than 11% on Wednesday after the company announced that it had signed a broad ...

Viking Therapeutics eyes billion-dollar obesity drug markets with pivotal trials and major production deals. Read more about ...

Viking announced a supply deal with CordenPharma that sets it up for a standalone path to the obesity market. Read why I ...

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a ...

The deal provides Viking Therapeutics with a secured dedicated annual supply of both injectable and oral versions of its ...

In a report released today, Joon Lee from Truist Financial maintained a Buy rating on Viking Therapeutics (VKTX – Research Report). The ...

Today, Benzinga's options scanner spotted 8 options trades for Viking Therapeutics. This is not a typical pattern. The ...

B. Riley analyst Mayank Mamtani reiterates a Buy rating on Viking Therapeutics (VKTX) with a $96 price target after the company announced a ...

VKTX’s shares are currently trading below the 50 and 200-day moving averages. The company is trading at a premium to the industry. Going by the price/book ratio, the stock currently trades at 4. ...